About the Company
Ageing is currently inevitable, but the new field of longevity research increasingly shows that we can slow down, and perhaps even halt, many of the effects of ageing. In 2021 we founded AVEA in Zug to help people stay fit and healthy longer at the highest level. We translate the latest research into simple, daily supplement routines.
Our products are developed in Switzerland in collaboration with leading scientists and institutions such as ETH Zurich, and their efficacy is tested in studies. This is how we developed the patented active ingredient Colgevity™ and proved its efficacy in a clinical study recently published by the Nature publishing group. Our products are available online across Europe and increasingly in pharmacies and specialist retailers. Well over 250,000 people rely on AVEA products on their journey to healthy ageing.
Company at a Glance
-
European market leader in a market of the future: unique patent and efficacy studies. Leading scientists on board
-
Dynamic growth: from under CHF 5 million in revenue in 2023 to over CHF 20 million in 2025, confirmed by our inclusion in the Sifted 250, Europe’s ranking of the fastest-growing startups. Already break-even in 2024.
-
Loyal customers: 60% of core revenue from active subscriptions, and more than 40% of subscribers still with us after 4 quarters.
-
Healthy fundamentals: over three years, customers bring in on average 4 times their acquisition cost.
-
Champions on board: top athletes like Lara Gut-Behrami, Sven Andrighetto and Iouri Podladtchikov recently joined as brand ambassadors and shareholders.
Benefits for Co-Owners and Investors
AVEA is aimed at investors who want to invest not simply in a good idea, but in the rapid growth of an already proven concept. The company is already profitable in its core business, its customers are loyal and the brand has been successfully launched in new markets.
The typical uncertainty of startup investments is further reduced by several factors:
-
An experienced team with deep professional and startup experience, led by the experienced entrepreneur Tobias Reichmuth
-
Strong existing distribution channels with D2C, Amazon and pharmacies
-
Patented and proprietary formulations and solid efficacy studies
-
Independent awards: the SEF.Growth High Potential Label from the Swiss Economic Forum and inclusion in the Sifted 250, the ranking of Europe’s 250 fastest-growing startups by revenue growth; highest-ranked Swiss startup in the Sifted 100: DACH & CEE 2026 ranking
Investors in this round are coming in at an attractive time:
-
Many experts, such as Goldman Sachs, see healthy ageing as one of the greatest opportunities of the century and see signs of the trend accelerating further.
-
The AVEA brand has already expanded successfully into individual markets in Europe and Asia and is now preparing to enter the world’s largest supplement market, the USA. The Swiss supplement and sports drink brand KA-EX shows how successful this can be: after its second Conda round, it successfully entered the US market and generated more revenue there than in Europe within a very short time. We partnered up with KA-EX to develop a ready to drink version of our Collagen Activator together that will be launched through KA-EX’s established US distribution channels by Q1 2027.
-
This round is deliberately the step before the next major growth phase: with the community’s capital, we are building the foundation for the US business and accelerating growth in Europe. For the full rollout in the USA, the world’s largest supplement market, we are planning a larger financing round (Series B) with institutional investors in 2027. Those who invest today via the convertible loan are on board before that round and convert at a discount to its valuation. The long-term goal remains an exit to a strategic buyer or private equity; recent acquisitions in the industry show the growing interest in science-based supplement brands.
We are looking for investors who believe in science-based supplements and a strong Swiss consumer brand – and who want to drive forward with us the vision of more healthy years of life for everyone.
As an investor, we involve you closely in our further development and give you exclusive access to our newest products for testing, as well as regular exclusive updates with our experts. Your feedback goes directly to our team that develops the products.
Milestones
2021
-
AVEA founded in Zug with lead investor Tobias Reichmuth
2022
-
Set-up of the sales companies and launch of the online shops in the UK and the DACH region
-
Launch of our first products: Vitality Bundle, Stabiliser and Collagen Activator (Raspberry)
-
Further research at ETH Zurich on our Collagen Activator
2023
-
Already over CHF 4 million in revenue.
-
Filing for the Colgevity™ patent (granted in 2025)
-
Launch of Mobiliser, Essentials and Cell Primer
2024
-
Market entry in Asia with strong growth of the platform business in China
-
Revenue more than tripled to over CHF 14 million.
-
Launch of Biomind and Collagen Activator (Lemon)
2025
-
Market entry in Italy – within one year, Italy became one of our three largest markets.
-
The efficacy of our patented active ingredient Colgevity™ is published in the scientific journal npj Aging.
-
Over CHF 20 million in revenue.
-
Launch of NR Vitaliser (B2B exclusive), NAD+ Test, Sereniser, SkinSpan™ and SkinSpan™ Skin Serum
2026
-
Launch in Swiss retail: BENU pharmacies, Manor and soon Globus.
-
Lara Gut-Behrami, Sven Andrighetto and Iouri Podladtchikov join as brand ambassadors and shareholders.
-
Named on the Sifted 250, Europe’s ranking of the fastest-growing startups, and highest-ranked Swiss startup in the Sifted 100: DACH & CEE ranking.
-
Launch of Magnesium Complex, Vegan Omega 3, MindSpan™ and MenoSpan™
-
Cover story in founded.ch magazine and launch of our crowdinvesting campaign on Conda.
Lara Gut-Behrami developing a Female Performance product together with Sophie Chabloz:
Sven Andrighetto with his daily AVEA Routine:
Testimonials
"I have been using AVEA products for quite awhile, and when the opportunity came up to help further shape the company’s development and contribute my experience, the answer was clear for me. I knew immediately: this is exactly what I want to do."
Lara Gut-Behrami
"I believe longevity is one of the defining topics of the 21st century, and supplements play a key role in it. Back then, we thought hard about where to find a great supplement company, and it quickly became clear: Swissness and a scientific approach are the two things that set AVEA apart from the rest."
Tobias Reichmuth, Entrepreneur
“I have been using AVEA products myself for a long time and I am truly convinced by them. They help me with energy, sleep and recovery”
Sven Andrighetto, Top Scorer, Swiss National Ice Hockey Team
Our Vision - Why invest in AVEA?
We believe that healthy ageing does not have to be a matter of luck. Everyone should have the chance to enjoy their best years for longer – with energy, clarity and joy of living. That is why we are building the leading European supplement brand focused on longevity.
The IM8 brand with David Beckham in the USA shows just how huge this market is: in only 20 months, the brand reached an annual revenue run rate of around USD 250 million. We are following the same path, but with Swiss precision and higher capital efficiency: our customers stay loyal to us, and our core business is already profitable.
In Italy we have shown what happens when we invest in a market in a targeted way: revenue grew eightfold within one year. With your investment, we roll out exactly this recipe to further European markets and lay the foundation for the world’s largest market: the USA. Become part of the movement and help us keep people fit and healthy at their highest level for longer.
FAQ
Why did you choose crowdinvesting as a form of financing?
Our core business is profitable, so a focused round is enough to accelerate growth in Europe and lay the foundation for the US market. For the full US rollout, we are planning a larger financing round with institutional investors in 2027. In addition, many of our loyal customers have expressed the wish to participate directly in AVEA’s success story, just like our ambassadors. This makes the round ideal for crowdfunding, in which private investors can also take part, and allows us to structure the round efficiently without limiting our strategic room for manoeuvre.
How did you come up with the company valuation?
This round deliberately has no fixed company valuation. You invest via a convertible loan that converts into participation certificates at our next larger financing round (Series B, planned for 2027), at a discount of 10-20% on that round’s valuation. The valuation is therefore not set by AVEA itself, but negotiated by the professional, institutional investors of the Series B. You benefit from their due diligence and negotiation, and thanks to the discount you invest on better terms than they do.
Should no Series B take place by the end of 2028, the conversion is governed by a formula fixed in the contract: a moderate revenue multiple on 2028 net revenue, derived from comparable transactions in the supplement industry, likewise with a discount. You therefore hold a stake in both scenarios. You can find all details in the investment agreement under Documents.
What examples of valuations do you have for similar companies?
Comparable brands have been valued at 2.9x to 8.0x revenue over the past two years, with a median of around 4.7x. The highest valuations went to brands with clinical credibility, loyal customers and a profitable business.
Do I get voting rights?
No. The crowdinvesting is structured as an economic participation. Voting rights remain with the existing shareholders, including the longevity company builder Maximon, led by experienced entrepreneurs such as Tobias Reichmuth and Marc P. Bernegger, and our founding team with backgrounds in science, consumer goods and e-commerce. This ensures fast and professional decision-making.
Will I receive dividends?
In the short to medium term, the focus is clearly on growth and reinvestment. Dividends are not currently planned. The primary return lever for investors is an increase in value in the context of an exit.
Is an exit planned?
Yes. The goal is an exit through acquisition in the 2029–2030 timeframe. Thanks to the strong brand and intellectual property in a strong market of the future, there is great interest from strategic investors in the consumer goods industry and from private equity funds. Good examples are the recent acquisitions of Grüns by Unilever, Bioniq by Herbalife, Thorne by Procter & Gamble and Huel by Danone, as well as CVC’s investment in Sunday Natural and Bain Capital’s acquisition of Vitabiotics.
Invest with us in one of the fastest-growing markets of the future: longevity and healthy ageing. Together with you, we want to grow AVEA from an established European startup into Europe’s leading supplement brand in longevity and gain a first foothold in the world’s largest supplement market, the USA.
As the capital requirement in this round is limited, the round may have to close early.
Over 20 years of experience in the financial industry and company building. From software engineer to management positions at Credit Suisse. Co-founder of the digital fund platform Fundbase, sold to ACOLIN in 2021. Then a founder in the foodtech and nutrition space as a passionate biohacker.
Food scientist from ETH Zurich (MSc Food Science, Nutrition & Health). Several years of industry experience at Coca-Cola as an Innovation Manager. At AVEA, she is responsible for research and development of the formulations, with a focus on synergistically combined ingredients.
Many years of experience in brand building and digital marketing. After positions in investment banking, she built up the markets at Foodspring as Global Head of Brand and, before that, was responsible for the brand of the health start-up Lykon as Head of Content. At AVEA, Teresa has shaped the brand and marketing from the very beginning.
Experienced e-commerce entrepreneur with several exits. He began his career at UBS Investment Bank and Boston Consulting Group, and moved into e-commerce with Rocket Internet 12 years ago. He was Co-CEO of Lazada Indonesia, at the time the country’s largest online marketplace, which was acquired by Alibaba in 2016 for over USD 3 billion. He then founded Mama’s Choice, a leading D2C brand for mothers and babies in Southeast Asia, with a successful exit.
Independent board member since 2026. Co-founder of Brame, the Zurich-based marketing technology company for gamification campaigns with clients such as KFC, SPAR and OBI, where he now sits on the board of directors. As an entrepreneur and investor, Tim brings deep expertise in digital marketing, customer loyalty and scaling growth companies.
Many years of leadership experience in customer service, sales and operations at companies such as Delivery Hero and Fidor Bank. At AVEA, Bella is responsible for customer service and the growing B2B business with pharmacies, retailers and distribution partners in Europe. Her focus: customer satisfaction and long-term customer relationships as the foundation of the brand.
Over ten years of experience in the sports industry, from sponsoring athletes and events to marketing sports products (including at AG1). At AVEA, Daniel is responsible for partnerships, PR and influencer marketing, including the collaboration with our brand ambassadors.